Monoclonal Antibodies For Inflammatory Bowel Disease Prominent At DDW
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Many firms involved in bowel disease drug development are seeking to identify subpopulations where new therapies can show activity, late-stage clinical data presented at the Digestive Disease Week meeting in New Orleans May 15-20 indicate.